Ethyl 2-(4'-bromophenyl)-1,3-oxazole-4-carboxylate, 95.0%, 1g

(R)-3-Acetamidopyrrolidine, 97.0%, 500mg

1-(Pyrimidin-2-yl)-1H-pyrazol-4-amine, 95.0%, 100mg

[(1-methyl-1H-pyrrol-2-yl)methyl](prop-2-en-1-yl)amine, 95.0%, 2g

4-Chloro-5-iodo-1H-pyrrolo[2,3-b]pyridine, 95.0%, 5g

(6-Methoxypyridin-2-yl)methanol, 95.0%, 25g

2,6-Dibromoanisole>98.0%(GC)1g

3-(1,1-Difluoroethyl)aniline, 97.0%, 5g

4-(Difluoromethoxy)benzonitrile, 98.0%, 5g

2,4-Dimethylstyrene, 97.0%, 250mg

Ethyleneglycol mono-tert-butyl ether, 99.0%, 500g

Plan PLPHi 20x/0.40 phase contrast IOS infinity corrected objective

Ethyl 3,3-dimethyloxirane-2-carboxylate, 95%, 1g